HRP20090334T1 - Kao inhibitori produkcije citokina za liječenje kroničnih upalnih bolesti - Google Patents
Kao inhibitori produkcije citokina za liječenje kroničnih upalnih bolestiInfo
- Publication number
- HRP20090334T1 HRP20090334T1 HR20090334T HRP20090334T HRP20090334T1 HR P20090334 T1 HRP20090334 T1 HR P20090334T1 HR 20090334 T HR20090334 T HR 20090334T HR P20090334 T HRP20090334 T HR P20090334T HR P20090334 T1 HRP20090334 T1 HR P20090334T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- optionally
- cr7r8
- substituted
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
Abstract
Spoj, naznačen time, da je formule (I) gdje: Ar1 je izabran između (i), (ii) i (iii) ispod: (i) ciklički ugljikovodik supstituiran s R1, R2 i Rx, (ii) gdje jedan od E ili F je dušik i drugi je ugljik, R1 je kovalentno vezan na E ili F, te kada je dušik N-R1 nema dvostruke veze između E i F; (iii) gdje c je benzenski prsten spojen na prsten d koji je 5 do 7 člani heterociklički prsten po izboru supstituiran s okso (=O) skupinom i jedna do dvije R skupina nezavisno jedna od druge je H ili C1-3 alkil; R1 je izabran iz skupine koju čine vodik, NO2, -N(Rc)2, J-C(O)-N(Rc)-, J-S(O)m-N(Rc)-, C1-6 alkilS(O)m-, ili R1 je izabran iz skupine koju čine C1-6 alkil, C3-7 cikloalkil, C1-5 alkoksil ili C3-7 cikloalkoksil, C1-5 alkiltiol ili C3-7 cikloalkiltiol, C1-5 acil, C1-5 alkoksikarbonil, C1-5 aciloksi, C1-5 acilamino, C2-5 alkenil, C2-5 alkinil, heterocikl, heterociklC1-6 alkil, heteroaril, heteroarilC1-6 alkil i nitril; pri čemu svaki od prije navedenih kada je to moguće može po izboru biti djelomično ili potpuno halogeniran ili može po izboru biti dalje supstituiran sa alkilsulfonilamino, aminokarboksil, alkoksil, amino, alkilamino, dialkilamino, hidroksil, okso, nitro ili nitril; R2 je izabran iz skupine koju čine: vodik, halogen, nitril, C1-5 alkilS(O)m-, arilS(O)m-, J-O-C(O)-O-, N(Rc)2-C(O)-(CH2)n-, C1-6 acetil, aroil, C1-6 alkoksikarbonil, C1-6 alkil, C3-7 cikloalkil, C1-6 alkoksi, C3-5 cikloalkoksi, C1-5 alkilC1-5alkoksi, hidroksi, hidroksiC1-5 alkil, te amino po izboru mono- ili di- supstituiran s C1-5 alkil, aril ili arilC1-5 alkil; pri čemu svaki od prije navedenih kada je to moguće može po izboru biti djelomično ili potpuno halogeniran ili može po izboru biti dalje supstituiran sa C1-3 alkil, alkilsulfonilamino, alkoksil, amino, alkilamino, dialkilamino, hidroksil, okso, nitro ili nitril; svaki Rx je izabran između C1-6 alkil ili C3-7 cikloalkil od kojih je svaki po izboru supstituiran sa C1-3 alkil i po izboru je potpuno ili djelomični halogeniran, C1-4 acil, aroil, C1-4 alkoksi, C1-5alkilS(O)m-, od kojih svaki može po izboru biti djelomično ili potpuno halogeniran, halogen, C1-6 alkoksikarbonil, karbociklosulfonil; svaki Rc je nezavisno vodik ili C1-5 alkil; D, A i B u formule (I) su svaki nezavisno izabrani između N ili CH gdje je atom vodika po izboru zamijenjen sa R6;Het je heterociklički ili heteroarilni prsten u kojem je Het po izboru supstituiran sa jednim do tri R5;m je 0, 1 ili 2; J je izabran između C1-10 alkil i C3-7 cikloalkil od koji je svaki po izbru upstituiran sa Rb;R3, R4, R6, R7 i R8 su svaki zasebno izbarani iz skuine koju čine vodik, halogen, C1-5 alkil, C1-5 alkoksi, C1-5 alkilC1-5 alkoksi, hidroksi, hidroksi C1-5 alkil ili amino po izboru mono- ili di- supstituiran sa C1-5 alkil, aril ili aril C1-5 alkil; R5 je: Ra, -O-Ra, -S(O)m-Ra, -N(Ra)2, -C(O)-Ra, -NH(CR7R8)n-Ra, N(Ra)2-(CH2)1-2-, -(CR7R8)n-Ra, -O(CR7R8)n-Ra, -C(O)-O(CR7R8)n-Ra, -C(O) (CR7R8)n-Ra-C(O)C(O)Ra, -C(O)C(O)ORa, -C(O)NHRa ili -C(O)NH(CR7R8)n-, od kojih svaki
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55144504P | 2004-03-09 | 2004-03-09 | |
PCT/US2005/006997 WO2005090333A1 (en) | 2004-03-09 | 2005-03-04 | 3-‘4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20090334T1 true HRP20090334T1 (hr) | 2009-07-31 |
Family
ID=34962594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20090334T HRP20090334T1 (hr) | 2004-03-09 | 2009-06-24 | Kao inhibitori produkcije citokina za liječenje kroničnih upalnih bolesti |
Country Status (30)
Country | Link |
---|---|
US (2) | US7214802B2 (hr) |
EP (2) | EP1887003A1 (hr) |
JP (1) | JP4850824B2 (hr) |
KR (1) | KR20060129077A (hr) |
CN (1) | CN1930144A (hr) |
AR (1) | AR048315A1 (hr) |
AT (1) | ATE432273T1 (hr) |
AU (1) | AU2005223738B2 (hr) |
BR (1) | BRPI0508561A (hr) |
CA (1) | CA2557856C (hr) |
CY (1) | CY1109333T1 (hr) |
DE (1) | DE602005014621D1 (hr) |
DK (1) | DK1725544T3 (hr) |
EA (1) | EA011634B1 (hr) |
EC (1) | ECSP066833A (hr) |
ES (1) | ES2327940T3 (hr) |
HR (1) | HRP20090334T1 (hr) |
IL (1) | IL177937A0 (hr) |
MY (1) | MY143000A (hr) |
NO (1) | NO20064120L (hr) |
NZ (1) | NZ550148A (hr) |
PE (1) | PE20051146A1 (hr) |
PL (1) | PL1725544T3 (hr) |
PT (1) | PT1725544E (hr) |
RS (1) | RS50796B (hr) |
SI (1) | SI1725544T1 (hr) |
TW (1) | TW200602313A (hr) |
UA (1) | UA85702C2 (hr) |
WO (1) | WO2005090333A1 (hr) |
ZA (1) | ZA200606177B (hr) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2647266A1 (en) * | 2006-04-18 | 2007-10-25 | Boehringer Ingelheim International Gmbh | Process for making cytokine inhibiting compounds containing 4- and 5- imidazolyl rings and the intermediates thereof |
NZ574621A (en) * | 2006-07-07 | 2012-03-30 | Boehringer Ingelheim Int | Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumour agents |
ATE532770T1 (de) | 2006-09-05 | 2011-11-15 | Kyowa Hakko Kirin Co Ltd | Imidazolderivat |
PE20090837A1 (es) * | 2007-07-02 | 2009-07-24 | Boehringer Ingelheim Int | Nuevos compuestos quimicos |
US20100240657A1 (en) * | 2007-07-02 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Chemical compounds |
US8278340B2 (en) * | 2007-11-27 | 2012-10-02 | North Carolina State University | Inhibition of biofilms in plants with imidazole derivatives |
US9005643B2 (en) | 2008-04-04 | 2015-04-14 | North Carolina State University | Inhibition of bacterial biofilms with imidazole-phenyl derivatives |
US7897631B2 (en) * | 2008-04-21 | 2011-03-01 | North Carolina State University | Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives |
BRPI0917693A2 (pt) * | 2008-09-02 | 2016-05-17 | Neurosearch As | composto derivado de triazol, composição farmacêutica, e, uso de um derivado de triazol |
AR073501A1 (es) | 2008-09-08 | 2010-11-10 | Boehringer Ingelheim Int | Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa |
CA2738448A1 (en) | 2008-09-29 | 2010-04-01 | Boehringer Ingelheim International Gmbh | New chemical compounds |
US9625475B2 (en) | 2008-09-29 | 2017-04-18 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
CN102227431A (zh) | 2008-09-29 | 2011-10-26 | 雅培制药有限公司 | 吲哚和二氢吲哚衍生物及其应用方法 |
WO2010077603A1 (en) * | 2008-12-08 | 2010-07-08 | North Carolina State University | Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives |
EP2398797B1 (en) | 2009-02-17 | 2013-11-06 | Boehringer Ingelheim International GmbH | Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases |
US9221765B2 (en) | 2009-06-10 | 2015-12-29 | North Carolina State University | Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives |
WO2011008312A2 (en) | 2009-07-14 | 2011-01-20 | Abbott Laboratories | Indole and indoline derivatives and methods of use thereof |
WO2011084434A2 (en) | 2009-12-17 | 2011-07-14 | Abbott Laboratories | Aza-ring fused indole and indoline derivatives |
WO2011084433A2 (en) | 2009-12-17 | 2011-07-14 | Abbott Laboratories | Aza-bridged ring-fused indoles and indolines |
CN104592233A (zh) | 2009-12-17 | 2015-05-06 | Abbvie公司 | 用于治疗神经变性和神经精神紊乱的桥头胺环稠合吲哚和二氢吲哚 |
KR20120099155A (ko) | 2010-01-07 | 2012-09-06 | 셀렉사겐 세라퓨틱스 인크. | 헤지호그 저해제 |
WO2011085261A1 (en) * | 2010-01-08 | 2011-07-14 | Selexagen Therapeutics, Inc. | Hedgehog inhibitors |
JP5871897B2 (ja) | 2010-03-26 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジルトリアゾール |
EP2552905B1 (en) | 2010-03-26 | 2016-10-05 | Boehringer Ingelheim International GmbH | B-Raf kinase inhibitors |
US8609669B2 (en) | 2010-11-16 | 2013-12-17 | Abbvie Inc. | Potassium channel modulators |
US8466181B2 (en) * | 2010-12-10 | 2013-06-18 | Hoffmann-La Roche Inc. | 1,2,3-triazole-imidazole compounds |
US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
HUE036027T2 (hu) * | 2011-01-28 | 2018-08-28 | Immunic Ag | IL17 és IFN-gamma inhibitorok autoimmun gyulladás kezelésére |
ES2664507T3 (es) * | 2011-01-28 | 2018-04-19 | Immunic Ag | Inhibición de IL17 e IFN-gamma para el tratamiento de una inflamación autoinmunitaria |
US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
WO2012158399A1 (en) | 2011-05-13 | 2012-11-22 | Abbott Laboratories | Condensed 2 - carbamoylpyridazinones as potassium channel modulators |
WO2013018695A1 (ja) | 2011-07-29 | 2013-02-07 | 武田薬品工業株式会社 | 複素環化合物 |
US9447099B2 (en) * | 2011-10-04 | 2016-09-20 | Hoffmann-La Roche Inc. | Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
EP3066083B1 (de) | 2013-11-05 | 2019-10-30 | Bayer Animal Health GmbH | Neue verbindungen zur bekämpfung von arthropoden |
AR107165A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
CA3052466A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ, インコーポレイテッド | Hbv複製阻害剤としての置換ピロリジン化合物 |
CN112055713A (zh) | 2018-03-01 | 2020-12-08 | 安娜普尔纳生物股份有限公司 | 用于治疗与apj受体活性有关的疾病的化合物和组合物 |
JP7391055B2 (ja) * | 2018-07-04 | 2023-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Gpr142アゴニストとしてのトリアゾールベンズアミド誘導体 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
EP4013750A1 (en) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
JOP20220087A1 (ar) | 2019-10-11 | 2023-01-30 | Incyte Corp | أمينات ثنائية الحلقة كمثبطات لـ cdk2 |
CN116761801A (zh) * | 2021-03-12 | 2023-09-15 | 四川科伦博泰生物医药股份有限公司 | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
FR2732967B1 (fr) | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
ATE294174T1 (de) * | 1996-06-10 | 2005-05-15 | Merck & Co Inc | Substituierte imidazole mit cytokinin- inhibirender wirkung |
JP4385414B2 (ja) * | 1997-10-13 | 2009-12-16 | アステラス製薬株式会社 | アミド若しくはアミン誘導体 |
AU751139B2 (en) * | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
JP2002510679A (ja) * | 1998-04-08 | 2002-04-09 | アボット・ラボラトリーズ | ピラゾールサイトカイン産生阻害剤 |
WO1999062885A1 (en) * | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
USRE45609E1 (en) | 1998-10-13 | 2015-07-14 | Covidien Lp | Multi-channel non-invasive tissue oximeter |
US6413992B1 (en) | 1998-10-23 | 2002-07-02 | Dow Agrosciences Llc | 3-(substituted pyridyl)-1,2,4-triazole compounds |
US6451820B1 (en) * | 2000-03-23 | 2002-09-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents |
US6498423B1 (en) | 2001-06-27 | 2002-12-24 | Welch Allyn, Inc. | Lamp thermal control by directed air flow |
WO2003022820A1 (en) | 2001-09-06 | 2003-03-20 | Bristol-Myers Squibb Pharma Company. | Heteroaromatic substituted cyclopropane as corticotropin releasing hormone |
WO2003030902A1 (en) | 2001-10-09 | 2003-04-17 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
WO2003063781A2 (en) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
ES2350837T3 (es) * | 2003-05-01 | 2011-01-27 | Bristol-Myers Squibb Company | Compuestos de pirazol-amida sustituidos con arilo útiles como inhibidores de quinasas. |
-
2005
- 2005-03-04 ES ES05724523T patent/ES2327940T3/es active Active
- 2005-03-04 UA UAA200610490A patent/UA85702C2/ru unknown
- 2005-03-04 KR KR1020067020618A patent/KR20060129077A/ko not_active Application Discontinuation
- 2005-03-04 AU AU2005223738A patent/AU2005223738B2/en not_active Ceased
- 2005-03-04 SI SI200530754T patent/SI1725544T1/sl unknown
- 2005-03-04 JP JP2007502866A patent/JP4850824B2/ja active Active
- 2005-03-04 RS RSP-2009/0256A patent/RS50796B/sr unknown
- 2005-03-04 CA CA2557856A patent/CA2557856C/en not_active Expired - Fee Related
- 2005-03-04 CN CNA2005800078734A patent/CN1930144A/zh active Pending
- 2005-03-04 PL PL05724523T patent/PL1725544T3/pl unknown
- 2005-03-04 NZ NZ550148A patent/NZ550148A/en unknown
- 2005-03-04 EP EP07112458A patent/EP1887003A1/en not_active Withdrawn
- 2005-03-04 AT AT05724523T patent/ATE432273T1/de active
- 2005-03-04 EA EA200601571A patent/EA011634B1/ru not_active IP Right Cessation
- 2005-03-04 DE DE602005014621T patent/DE602005014621D1/de active Active
- 2005-03-04 WO PCT/US2005/006997 patent/WO2005090333A1/en active Application Filing
- 2005-03-04 EP EP05724523A patent/EP1725544B1/en active Active
- 2005-03-04 PT PT05724523T patent/PT1725544E/pt unknown
- 2005-03-04 DK DK05724523T patent/DK1725544T3/da active
- 2005-03-04 BR BRPI0508561-6A patent/BRPI0508561A/pt not_active IP Right Cessation
- 2005-03-07 MY MYPI20050920A patent/MY143000A/en unknown
- 2005-03-07 US US11/074,354 patent/US7214802B2/en active Active
- 2005-03-07 PE PE2005000254A patent/PE20051146A1/es not_active Application Discontinuation
- 2005-03-08 TW TW094106994A patent/TW200602313A/zh unknown
- 2005-03-09 AR ARP050100899A patent/AR048315A1/es active Pending
-
2006
- 2006-07-26 ZA ZA200606177A patent/ZA200606177B/xx unknown
- 2006-09-07 IL IL177937A patent/IL177937A0/en unknown
- 2006-09-08 EC EC2006006833A patent/ECSP066833A/es unknown
- 2006-09-13 NO NO20064120A patent/NO20064120L/no not_active Application Discontinuation
-
2007
- 2007-01-30 US US11/668,704 patent/US7514458B2/en active Active
-
2009
- 2009-06-24 HR HR20090334T patent/HRP20090334T1/hr unknown
- 2009-08-24 CY CY20091100893T patent/CY1109333T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20090334T1 (hr) | Kao inhibitori produkcije citokina za liječenje kroničnih upalnih bolesti | |
RS53059B (en) | NEW SUBSTITUTED IMIDAZOCHINOLINES | |
RU2007105995A (ru) | Новые соединения, обладающие антибактериальной активностью | |
ATE540037T1 (de) | Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten | |
RS52562B (en) | (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I | |
NO20065830L (no) | Substituerte 2-kinolyloksazoler som er anvendbare som PDE4-inhibitorer. | |
ME01089B (me) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
PE20080318A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
RS52210B (en) | CYCLOPENT [D] PYRIMIDINS AS PROTEIN KINASE ACTION INHIBITORS | |
RS51782B (en) | AZETIDINS AS MAK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
RS52451B (en) | PHENYLPROPIONAMIDE COMPOUNDS AND THEIR USE | |
AR048346A1 (es) | Piridonas sustituidas como inhibidores de poli(adp-ribosa)-polimerasa (parp), composiciones farmaceuticas que las contienen y el uso de las mismas para el tratamiento de trastornos cardiovasculares y del sistema nervioso central. | |
MEP22008A (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
EA200600527A1 (ru) | Активирующее ppar соединение и содержащая его фармацевтическая композиция | |
RU2011106374A (ru) | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 | |
NO20082934L (no) | Antivirale nukleotider | |
MX2010007525A (es) | Derivados de indolil-piridona que tienen actividad inhibitoria de la cinasa 1 de punto de control. | |
EA200870192A1 (ru) | Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ | |
RS53627B1 (en) | N- (3-Amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
HRP20020175B1 (hr) | N-heterociklički derivati kao inhibitori nos | |
AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
HRP20080592T3 (hr) | DERIVATI 3-FENIL-PIRAZOLA KAO MODULATORI 5-HT-2a SEROTONIN RECEPTORA KORISNI ZA LIJEČENJE POREMEĆAJA POVEZANIH S NJIMA | |
HUP0302226A2 (hu) | Foszfodiészteráz inhibitorokként alkalmazható szubsztituált pirrolopiridinon-származékok, ezek intermedierjei és a vegyületeket tartalmazó gyógyszerkészítmények | |
MX2009011212A (es) | Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica. |